Sjögren's syndrome: Managed care data from a large United States population highlight real-world health care burden and lack of treatment options

Clinical and Experimental Rheumatology

Volumn 35, Issue 1, 2017, Pages 98-107

  Birt, Julie A ^a   Tan, YingMeei ^a   Mozaffarian, Neelufar ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anti rheumatic agents; Autoimmunity; Biological products; Cardiovascular diseases; Drug utilisation; Health care costs; Insurance claim reporting; Sj gren's syndrome

Indexed keywords

ALCLOMETASONE; AMCINONIDE; BETAMETHASONE; CELECOXIB; CEVIMELINE; CLOBETASOL; CLOCORTOLONE; CYCLOSPORIN; DESONIDE; DESOXIMETASONE; DEXAMETHASONE; DICLOFENAC; DIFLORASONE; FENOPROFEN; FLUDROXYCORTIDE; FLUOCINOLONE; FLUOCINONIDE; FLURBIPROFEN; FLUTICASONE; HALCINONIDE; HYDROCORTISONE; IBUPROFEN; KETOROLAC; METHYLPREDNISOLONE; MOMETASONE FUROATE; PILOCARPINE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FIBROMYALGIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNIST; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MANAGED CARE; MENTAL DISEASE; OBSERVATIONAL STUDY; OSTEOARTHRITIS; OSTEOPOROSIS; PARASITOSIS; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; UNSTABLE ANGINA PECTORIS; FACTUAL DATABASE; INSURANCE; MIDDLE AGED; SJOGREN'S SYNDROME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE CLAIM REPORTING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; UNITED STATES;

EID: 85013213413     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. PATEL R, SHAHANE A: The epidemiology of Sjögren's Syndrome. Clin Epidemiol 2014; 6: 247-55
2. HALL SA, JUNEJA M, VINIKOOR L, MUSSELLI C, FRANCHIMONT N: The prevalence of Sjögrens's Syndrome in United States health insurance claims. Pharmacoepid Drug Saf 2015; 24: 371-72
3. SHIBOSKI SC, SHIBOSKI CH, CRISWELL LA et al.: American College of Rheumatology Classification Criteria for Sjögren's Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. Arth Care Res 2012; 64: 475-87
4. http://info.sjogrens.org/conquering-sjogrens/bid/359061/Ask-the-SSF-Staff-Treating- Primary-vs-Secondary-Sjögren-s. Accessed January 26, 2016
5. FOX PC: Autoimmune diseases and Sjögren's Syndrome. An autoimmune exocrinopathy. Ann NY Acad Sci 2007; 1098: 15-21
6. GARCIA-CARRASCO M, RAMOS-CASALS M, ROSAS J et al.: Primary Sjögren's Syndrome. Clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002; 81: 270-80
7. RAMOS-CASALS M, BRITO-ZERON P, BOADA AB, SISO-ALMIRALL A: Sjögren's Syndrome: beyond sicca involvement. Autoimmune Dis 2011 DOI: 10.1007/978-0-85729-358-9_5
8. SEROR R, BOOTSMA H, BOWMAN SJ et al.: Outcome measures for primary Sjögren's syndrome. J Autoimmun 2012; 39: 97-102
9. TINCANI A, ANDREOLI L, CAVAZZANA I et al.: Novel aspects of Sjögren's syndrome in 2012 BMC Medicine 2013; 11: 93-109
10. SEROR R, GOTTENBERG JE, DEVAUCHELLEPENSEC V et al.: European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient- Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients. Arthritis Care Res 2013; 65: 1358-64
11. RAMOS-CASALS M, BRITO-ZERÒN P, SISÒ- ALMIRALL A, BOSCH X: Primary Sjögren syndrome. BMJ 2012, 344:e3821
12. SUTCLIFFE N, STOLL T, PYKE S, ISENBERG DA: Functional disability and end organ damage in patients with Systemic Lupus Erythematosus (SLE), SLE and Sjögren's Syndrome, and Primary SS. J Rheumatol 1998; 25: 63-8
13. STROMBECK B, EKDAHL C, MANTHORPE R, WIKSTROM I, JACOBSSON L: Health related quality of life in primary Sjögren's Syndrome, rheumatoid arthritis, and fibromyalgia compared to normal population data using the SF36. Scand J Rheumatol 2000; 29: 20-8
14. SEGAL B, BOWMAN SJ, FOX PC et al.: Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009; 7: 46
15. CALLAGHAN R, PRABU A, ALLAN RB et al.: Direct healthcare costs and predictors of cost in patients with Primary Sjögren's Syndrome. Rheumatology 2007; 46: 105-11
16. BOWMAN SJ, St PIERRE Y, SUTCLIFFE N et al.: Estimating indirect costs in primary Sjögren's Syndrome. J Rheumatol 2010; 37: 1010-5
17. GOTTENBERG JE, RAVAUD P, PEUCHAL X et al.: Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren's Syndrome: The JOQUER randomized clinical trial. JAMA 2014; 312: 249-58
18. RAMOS-CASALS M, BRITO-ZERON P, SISOALMIRALL A, BOSCH X, TZIOUFAS AG: Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8: 399-411
19. BOWMAN S, BARONE F: Biologic treatments in Sjögren's syndrome. Presse Med 2012; 41: e495-e509
20. MARIETTE X, RAVAUD P, STEINFELD S et al.: Inefficacy of infliximab in primary Sjögren's Syndrome. Results of the randomized, controlled trial of Remicade in primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270-74
21. SANKAR V, BRENNAN MT, KOK MR et al.: Etanercept in Sjögren's Syndrome. A twelve week randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum 2004; 50: 2240-5
22. ZANDBELT MM, De WILDE P, Van DAMME P et al.: Etanercept in the treatment of patients with primary Sjögren's Syndrome: A pilot study. J Rheum 2004; 31: 96-101
23. http://truvenhealth.com/your-healthcare-focus/life-sciences/marketscan-databases-andonline- tools. Accessed January 26, 2016
24. BERNATSKY S, LINEHAN T, HANLY JG: The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011; 38: 1612-16
25. MAVRAGANI CP, MOUTSOPOULOS HM: The geoepidemiology of Sjögren's Syndrome. Autoimmun Rev 2010; 9: A305-A310
26. GRAVANI F, PAPADAKI I, ANTYPE A et al.: Subclinical atherosclerosis and impaired bone health in patients with primary Sjögren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 2015; 17: 99
27. FERRO F, VAGELLI R, BRUNI C et al.: One year in review 2016: Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 161-71
28. VALIM V, GERDTS E, JONSSON R et al.: Atherosclerosis in Sjögren's syndrome: evidence, possible mechanisms and knowledge gaps. Clin Exp Rheumatol 2016; 34: 133-42
29. JUAREZ M, TOMS TE, DEPABLO P et al.: Cardiovascular risk factors in women with primary Sjögren's Syndrome: United Kingdom Primary Sjögren's Syndrome Registry results. Arthritis Care Res 2014; 66: 757-64
30. BARTOLONI E, BALDINI C, SCHILLACI G et al.: Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. J Intern Med. 2015; 278: 185-92
31. AVINA-ZUBIETA JA: Increased cardiovascular risk in Sjögren's Syndrome. European League against Rheumatism, 2014 Annual Meeting, Paris, France
32. SADA PR, ISENBERG D, CIURTIN C: Biologic treatment in Sjögren's Syndrome. Rheumatology 2015; 54: 219-30
33. CARUBBI F, ALUNNO A, CIPRIANI P et al.: Rituximab in primary Sjögren's Syndrome: a ten-year journey. Lupus 2014; 23: 1337-49
34. DEVAUCHELLE-PENSEC V, MARIETTE X, JOUSSE-JOULIN S et al.: Treatment of primary Sjögren's Syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160: 233-42
35. LEE SJ, CHANG H, YAZICI Y, GREENBERG JD, KREMER JM, KAVANAUGH A: Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 2009; 36: 1611-7
36. KAWATKAR AA, JACOBSEN SJ, LEVY GD, MEDHEKAR SS, VENKATASUBRAMANIAM KV, HERRINTON LJ: Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the Medical Expenditure Panel Survey. Arthritis Care Res 2012; 64: 1649-56
37. Sjögren's Syndrome Foundation: Written Testimony from Steven Taylor, Sjögren's Syndrome Foundation CEO House Ways and Means Oversight Subcommittee Hearing: "The Impact of Limitations on the Use of Tax-Advantaged Accounts for the Purchase of Over-the-Counter Medication" April 25, 2012